KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teladoc Health (TDOC) EBITDA (2016 - 2025)

Teladoc Health's EBITDA history spans 12 years, with the latest figure at -$25.3 million for Q4 2025.

  • For Q4 2025, EBITDA rose 49.16% year-over-year to -$25.3 million; the TTM value through Dec 2025 reached -$196.7 million, up 80.39%, while the annual FY2025 figure was -$196.7 million, 80.39% up from the prior year.
  • EBITDA for Q4 2025 was -$25.3 million at Teladoc Health, up from -$48.7 million in the prior quarter.
  • Across five years, EBITDA topped out at $54.5 million in Q1 2022 and bottomed at -$10.5 billion in Q4 2022.
  • The 5-year median for EBITDA is -$65.2 million (2023), against an average of -$778.2 million.
  • The largest YoY upside for EBITDA was 125.57% in 2022 against a maximum downside of 65197.68% in 2022.
  • A 5-year view of EBITDA shows it stood at -$16.1 million in 2021, then tumbled by 65197.68% to -$10.5 billion in 2022, then soared by 99.77% to -$24.4 million in 2023, then crashed by 103.99% to -$49.7 million in 2024, then surged by 49.16% to -$25.3 million in 2025.
  • Per Business Quant, the three most recent readings for TDOC's EBITDA are -$25.3 million (Q4 2025), -$48.7 million (Q3 2025), and -$30.8 million (Q2 2025).